UNSPSC 51343703: Rilpivirine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C22H18N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FI96A8X663, chemically known as 4-((4-((4-((1e)-2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile but generally known as rilpivirine, which bears US NIH Compound Identifier 6451164. European Medicines Agency schedules Rilpivirine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31456.

UNSPSC 51343703 Rilpivirine, a Commodity code, does not align with the state and local procurement activity recently tagged under it. The code nominates a specific antiretroviral pharmaceutical (rilpivirine), yet the four recent opportunities posted under this code solicit naloxone and drug deactivation systems, first aid and emergency medical supplies, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription program capabilities—none of which are rilpivirine. The mismatch suggests either miscoding in the source system or a taxonomy alignment issue. State and local governments do purchase pharmaceuticals through this and related codes, as evidenced by active solicitations from county health departments, state health and human services commissions, municipal fire departments, and cooperative purchasing alliances, but the rilpivirine code itself shows no relevant recent activity.

The issuing bodies span diverse jurisdictions: Seminole County, Florida (health procurement); the Texas Health and Human Services Commission (state-level pharmacy benefit strategy); the City of Tampa (municipal fire-rescue medical supplies); and the Minnesota Department of Administration administering MMCAP, a multistate cooperative purchasing vehicle serving state and local government facilities across Minnesota and Oregon. Geographic activity centers on Florida, Texas, and the Upper Midwest, with cooperative purchasing extending across multiple states. Representative solicitations include Seminole County's IFB 60459723LAS (naloxone and drug deactivation systems, due July 26, 2023), the City of Tampa's ITB 26P00145 for medical and first aid supplies with a $700,000 estimated value and SLBE 5% bid discount (due March 13, 2026), Texas HHS Commission's RFI HHS0017013 on direct-to-manufacturer prescriptions (due April 3, 2026), and MMCAP's RFP S1070000015802 for generic pharmaceuticals and OTC products through authorized wholesalers (due March 26, 2026). Without confirmed rilpivirine-specific opportunities, this code presents limited current pursuit opportunity in its nominal form.